No Data
No Data
Jaguar Health's Stock Slides 68% After Cancer Trial Fails to Meet Main Goal
US Stocks Edge Higher; General Motors Posts Upbeat Earnings
Express News | Jaguar Health Is Trading Lower After the Company Announced Its Phase 3 OnTarget Trial Results for Crofelemer Did Not Meet Its Primary Endpoint
Express News | Jaguar Health Announces Webcast On July 23 To Discuss Phase 3 OnTarget Trial Results For Crofelemer
Express News | Jaguar Health - Initial Results From Ontarget Study Show That Multicenter, Double-Blind, Placebo-Controlled Pivotal Clinical Trial Did Not Meet Primary Endpoint
Express News | Jaguar Health Reports Phase 3 Ontarget Trial Results for Its Cancer Supportive Care Drug Crofelemer
No Data
104792407 : if lisa conte resigns.